Added to YB: 2026-04-03
Pitch date: 2026-04-02
LNSR [neutral]
LENSAR, Inc.
Author Info
No bio for this author
Company Info
LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing laser systems for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism in the United System, Europe, Asia, South Korea, and internationally.
Market Cap
$72.1M
Pitch Price
N/A
Price Target
10.00 (+65%)
Dividend
N/A
EV/EBITDA
-3.65
P/E
-2.08
EV/Sales
1.21
Sector
Health Care Equipment and Supplies
Category
turnaround
Update LENSAR (LNSR): Q4 Earnings Update and the Real Impact of the Failed Alcon Acquisition
LNSR (earnings): Q4 proc vol record 54,756 (+20% YoY), recur rev +17% to $12.7M (79% of total), click-fee stable at $164. System rev -43% to $3.4M on Alcon M&A chill: 12mo FTC review, $17M costs, intl distrib froze (1 intl system Q4 vs 10 prior yr). 2026 transition yr, 2027 recovery target. $10 PT in 12-18mo on 0.9x rev.
Read full article (6 min)